

## Seznam portugalskih podjetij v delegaciji

3. 3. 2025

Sector	Company/ Institution name	WebPage	Company/Institution Description & Products/Services/Competences	Slovenian companies/institutions we would like to meet
PHARMACEUTICAL	BIAL	<a href="https://www.bial.com/pt/">https://www.bial.com/pt/</a>	<p>BIAL is a hundred-year-old innovation-driven biopharmaceutical company dedicated to discovering, developing, and commercializing medicines to improve people's lives worldwide. Strongly committed to therapeutic innovation, BIAL has established an ambitious R&amp;D program, consistently investing more than 20% of its annual revenue in this field. Key focus areas for the company are the neurosciences and rare diseases.</p> <p>BIAL has launched two innovative medicines: an epilepsy drug, and a Parkinson's disease treatment. The launch of its research drugs was crucial to boosting BIAL's internationalization. In Europe, BIAL has a production site and R&amp;D unit in Portugal (HQ) and affiliates in several countries - Spain, Germany, United Kingdom, Italy, and Switzerland. Additionally, BIAL is present in the US and in some emerging markets such as Angola and Ivory Coast.</p> <p>The company's internationalization strategy also sought to establish partnerships and license agreements, thus collaborating with well-established partners to bring health solutions to everyone in need, namely in the US, Japan, China, Australia, and South Korea. BIAL products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people living with severe diseases across the world.</p>	Investigation Centres in neuroscience and rare diseases

PHARMACEUTICAL	TECNIMEDE	<a href="http://www.tecnimede.com">www.tecnimede.com</a>	<p>Tecnimede Sociedade Técnico Medicinal S.A. (Portugal), are a privately owned group of pharmaceutical companies dedicated to the development, registration, manufacturing, promotion and sale of pharmaceutical products for human use.</p> <p>Tecnimede Group is present through subsidiaries in Spain, Italy, Colombia, Brazil, and Morocco. Our direct commercial operations cover generics, Consumer Healthcare, as well as innovative prescription medicines.</p> <p>We have a strong position in the generic medicines market and Value Added Medicine Market with a clear orientation to quality and technological innovation. Considering R&amp;D activities as a key factor in our development strategy, Tecnimede Group has been distinguished by Portuguese governmental institutions for its investment of important financial resources in R&amp;D Activities. Working with CROs in Spain and Canada, we have a large experience in conducting BD / BE studies and a portfolio of more than 100 generic medicines that are being registered (locally or by DCP) all over Europe and worldwide. As a group we are the 2nd company of the Portuguese Market, the 1st 100% Portuguese company and one of the fastest growing enterprises of such ranking.</p>	<p>Pharmaceutical companies with a presence in the Slovenian pharmaceutical market and or in the Region, interested in evaluating opportunities for cross licenses (mutual In and Out-Licensing) or co-developments of pharmaceutical Products for Human Health. Contract Manufacturing Countries</p>
----------------	-----------	--	---	---

PHARMACEUTICAL	SIDEFARMA- Sociedade Industrial de Expansão Farmacêutica S.A.	<a href="https://www.sidefarma.pt/">https://www.sidefarma.pt/</a>	<p>SIDEFARMA is a Portuguese pharmaceutical company with nearly 50 years of experience, specializing in the manufacturing and commercialization of pharmaceutical products for regulated markets. We export to over 20 countries across Europe, Africa, Asia, Latin America, and the Middle East.</p> <p>Our expertise lies in small to medium batch production for third parties, ensuring compliance with European regulatory guidelines. Additionally, we promote our own branded products through B2B partnerships worldwide. SIDEFARMA is recognized for its high-quality pharmaceutical solutions, benefiting from Portugal's strict regulatory framework and a strong production environment.</p>	<p>We seek to establish B2B meetings with Slovenian pharmaceutical companies, distributors, and wholesalers interested in high-quality pharmaceutical products. Our primary focus is on companies looking for contract manufacturing solutions (small to medium batch production) that comply with European regulatory standards. Additionally, we are keen to connect with potential partners for licensing, distribution of our branded products.</p>
PHARMACEUTICAL	Hikma Farmaceutica	<a href="http://www.hikma.com">www.hikma.com</a>	<p>Hikma Pharmaceuticals is a global group specializing in the development, manufacturing, and marketing of high-quality, affordable generic medicines. With a strong presence in the US, Europe, and the Middle East, Hikma is a key player in the pharmaceutical industry.</p> <p>In Portugal, Hikma has a significant footprint, serving as the Global Center of Excellence for injectable medicines. Hikma Farmacêutica Portugal operates a state-of-the-art industrial campus in Sintra, near Lisbon, employing over 1,000 workers and utilizing advanced pharmaceutical technologies. This facility underscores Hikma's commitment to innovation and excellence in the production of injectable medicines for global markets.</p>	<ul style="list-style-type: none"> <li>· Krka, d.d., Novo mesto</li> <li>· Lek d.d. (Sandoz)</li> <li>· Acies Bio</li> <li>· Porton Pharma Solutions</li> </ul>

PHARMACEUTICAL	BLUEPHARMA INDÚSTRIA FARMACÊUTICA S.A.	<a href="https://www.bluepharmagroup.com/">https://www.bluepharmagroup.com/</a>	<p>Bluepharma is a Portuguese pharmaceutical company headquartered in Coimbra, established in 2001 following Bayer's disinvestment in Portugal. Over two decades, it has grown into an innovation-driven group, integrating multiple technology-based companies and expanding its highly qualified workforce.</p> <p>Operating across the entire pharmaceutical value chain, Bluepharma specializes in R&amp;D, manufacturing, licensing and commercialization of medicinal products, adhering to the highest quality standards. Its expertise spans oral formulations, complex injectables, and high-potency medicines, with GMP-certified facilities and a new sterile manufacturing site under development.</p> <p>With a strong commitment to innovation and international expansion, Bluepharma invests heavily in oncology, nanotechnology, and advanced drug delivery systems. Through strategic partnership and bold vision for the future, it continues to shape the pharmaceutical industry with excellence, agility, and global impact.</p>	<p>We are looking to engage with Slovenina pharmaceutical companies, CDMOs (Contract Development and Manufacturing Organizations), biotech firms, and research institutions that specialize in drug development, manufacturing, and innovative delivery systems (focus advanced therapies). Specifically, we are interested in companies with expertise in:</p> <ul style="list-style-type: none"> <li>- Complex injectables, sterile manufacturing, and lipid-based drug delivery</li> <li>- Nanotechnology / nanomedicine</li> <li>- Companies seeking partnership for licensing, co-development, or contract manufacturing</li> </ul> <p>Our goal is to explore potential collaborations, strategic partnerships, and technology-sharing opportunities that align with</p>
----------------	---	---	--	---



				<p>Bluepharma's focus on innovation.</p>
--	--	--	--	--

<p><b>BIOTECH</b></p> <p>HealthTech</p>	<p><b>EIT Health InnoStars</b></p>	<p><a href="https://eithealth.eu">https://eithealth.eu</a></p>	<p>EIT Health is one of eight Knowledge and Innovation Communities (KICs) of the European Institute of Innovation and Technology (EIT), an EU body. EIT Health is an Institutionalised Partnership under Horizon Europe's Pillar III – Innovative Europe. Established in 2015 to tackle the societal challenges of 'health, demographic change and well-being' within the EU, its mission is to help overcome the well-known EU paradox whereby state-of-the-art education, excellent research and a dynamic industry are challenged to turn breakthrough ideas into new transformative products and services. Within the EIT Health network, ~130 partner organisations and institutions from academia, business, research and health care delivery collaborate across disciplines, borders and sectors to reinforce excellence, create knowledge and innovation and encourage greater investment in innovation that delivers the outcomes that matter to citizens and patients. As a result, EIT Health represents a unique match between a sustainable innovation ecosystem model gathering and leveraging different partners and funding sources, and a change agent with extensive capacity to generate real-world data for evidence-based policymaking and the transformation of health care.</p> <p>EIT Health InnoStars is one of the regional divisions of EIT Health, focusing on Southern, Central, and Eastern European countries with moderate innovation capacity. It supports healthcare startups, SMEs, and innovators through funding, mentoring, and acceleration programs to foster the development of new health solutions. InnoStars aims to bridge the gap between research and market adoption, strengthening regional ecosystems and promoting collaboration between academia, industry, and healthcare providers.</p>	<p>Biotech, Medtech and Digitech SME and Corporate Healthcare Providers: Hospitals (public and private); National Healthcare System representatives Startup Incubators/Accelerators or R&amp;D Institutions; Clinical Trial Units, etc National Innovation Agencies/entities</p>
---	--	--	--	--

<p><b>BIOTECH</b></p>	<p><b>Genlbet Biopharmaceutic als (fully owned subsidiary from Recipharm A.B. )</b></p>	<p><a href="http://www.recipharm.com">www.recipharm.com</a></p>	<p>Founded in 2006, as a spin-off company from iBET (a private non-profit research-intensive organization in Biotechnology and Life Sciences), Genlbet was the 1st Portuguese CDMO to supply Biopharmaceuticals for Clinical Trials. Genlbet was also the 1st Portuguese company, in 2009, to obtain a Good Manufacturing Practices (GMP) certification, recognized by the European Medicines Agency, to produce Biological Investigational Medicinal Products (IMPs). Genlbet was approved in 2023 by FDA for the manufacturing of the first commercial oral microbiome product – VOWST.</p> <p>Genlbet is located in Oeiras, Portugal 20 km away from Lisbon airport and supports early-to-late phase clinical programs and commercial manufacturing. Genlbet expertise covers a broad spectra of Biopharmaceuticals development and manufacturing, including biological banks of mammalian and insect cells, bacteria, yeasts and virus, Cell and Gene Therapy products, Live Microbial Products, Recombinant proteins, RNA and Vaccines.</p> <p>Genlbet Biopharmaceutical S.A. is, since January 2022, part of Recipharm AB, a global contract development and manufacturing organization (CDMO) operating in over 12 countries.</p>	<p>Innovator companies working on drug development and looking for GMP manufacturing services.</p>
<p><b>BIOTECH</b></p> <p>Research &amp; Innovations</p>	<p><b>Centre for Innovative Biomedicine and Biotechnology of the University of Coimbra</b></p>	<p><a href="https://cibb.uc.pt/en">https://cibb.uc.pt/en</a></p>	<p>The Center for Innovative Biomedicine and Biotechnology (CIBB) is recognized as a research unit of excellence and a reference in biomedicine and biotechnology. With over 700 researchers, CIBB is the largest R&amp;D unit in central Portugal, housing 37 research groups across three main thematic areas: Neuroscience &amp; Disease, Metabolism, Ageing &amp; Disease and Innovative Therapies, along with an emerging focus on Healthcare Challenges. The center excels in international collaboration with different sectors, including other research institutes, industries, hospitals, government bodies and patient associations. CIBB also possesses state-of-the-art laboratory infrastructures and core facilities to support high-level studies across various biomedical fields, including advanced microscopy, flow cytometry, electrophysiology, mass</p>	<p>We are interested in connecting with Slovenian companies specializing in biotechnology, pharmaceuticals, and medical devices, particularly those focused on gene and cell therapy, precision medicine, and advanced biomedical research. Companies with</p>

			<p>spectrometry, next-generation sequencing, high throughput screenings, and viral production, some of which are recognized on the National Roadmap for Research Infrastructures. CIBB's research has led to multiple scientific discoveries (over 3,400 publications in top scientific journals), knowledge and technology transfer, clinical translation, and societal impact.</p>	<p>expertise in biomanufacturing, diagnostic tools, or AI-driven healthcare solutions would be valuable partners. Additionally, we welcome collaborations with CROs, CDMOs, and biotech startups engaged in translational research, clinical applications, or technology transfer in biomedicine and healthcare innovation.</p>
MEDICAL DEVICES	ADA Group	<a href="http://www.ada.pt">www.ada.pt</a>	<p>Albino Dias Andrade, S.A. (Ada Group) is a company specialized in the development, manufacture and distribution of medical devices. With a strong commitment to innovation and quality, ADA Group provides advanced solutions for the healthcare sector, meeting the needs of medical professionals and patients with reliable and high-performance products. ADA Group's excellence extends to the production of medical devices, where we are leaders in scale and efficiency. We produce 350 million gauze and non-woven swabs, 35 million bandages, 8 million underpads and 3.5 million diapers per month. These impressive figures translate into solutions that combine sustainability, technology and innovation, always with the aim of meeting the growth demands of the global market.</p>	<p>Given our focus on the development, manufacture and distribution of medical devices, we would like to schedule B2B meetings with companies operating in the medical device, healthcare and related technology sectors. We are looking for strategic partners for possible collaborations.</p>



<b>HEALTH</b>	<b>Health Cluster Portugal</b>	<a href="http://www.healthportugal.com">www.healthportugal.com</a> <a href="http://www.healthclusterportugal.pt">www.healthclusterportugal.pt</a>	<p>Health Cluster Portugal (HCP) is a private non-profit association, founded in 2008, that currently brings together more than 220 members, including R&amp;D institutions, universities, hospitals, organisations from civil society, and companies in the areas of pharmaceuticals, biotechnology, medical technologies, and services.</p> <p>Together, HCP and its members develop innovative projects in areas such as translational and Clinical Research, Smart Health, e-Health, Medical Devices, Medtech, Active and Healthy Ageing and Health Tourism, with the purpose of turning knowledge into new products and services that contribute to the improvement of human health and wellbeing, improve health solutions exportations and to make Portugal the right place to invest and build partnerships in Health.</p>	Health Clusters and/or metaclusters, like Scanbalt ( <a href="https://scanbalt.org">https://scanbalt.org</a> )
<b>AUTOMOTIVE</b> Metallurgical	<b>TORMETAIS-SOC.COM. DE METAIS LDA</b>	<a href="http://www.tormetais.com">www.tormetais.com</a>	Tormetais - Sociedade de Comercialização de Metais, Lda, is based on the mass production of turned parts and light stamping in ferrous and non-ferrous metals.	Our main sector is automotive, however we are looking for new customers in other areas that require turned parts with mass production.
<b>AUTOMOTIVE</b> Automotive and Mobility	<b>Mobinov – Portuguese automotive and mobility cluster</b>	<a href="http://www.mobinov.pt">www.mobinov.pt</a>	Mobinov is a platform for aggregating knowledge and competence within the automotive industry, with the aim of promoting an increasing enhancement of competitiveness and internationalization of the sector. On the other hand, it aims to contribute to turning Portugal into a reference in research, innovation, design, development, manufacturing and testing of products and services in the automotive industry.	With Slovenian automotive cluster, OEM's, component suppliers, technological centers.